GeneriCo develops and markets niche generic pharmaceuticals built around unique drug delivery formats and formulations. The company is led by President and CEO Tom Brya and is based in St. Louis, MO. Its pipeline includes 22 potential drug formulations and contract distribution rights for several additional drugs. GeneriCo plans to use the newly raised capital to expand operations over the next 18 months. The company also anticipates raising a Series B round in Q3 2016. Current financing activity suggests the firm is in an early commercial/scale-up phase, investing proceeds to grow operations and advance its pipeline.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2015